OncoGenex Sinks on Failed Experimental Prostate Cancer Treatment Results; JC Penney Climbs Higher

Follow this company

Companies Mentioned

04/29/2014 [ACCESSWIRE]

J.C. Penney Company, Inc. (NYSE: JCP) – For an in-depth report on J. C. Penney Company, Inc. follow: www.BullTrends.com/stockquote/JCP

Shares of J. C. Penney closed up 9.02% on nearly 35 million shares on Monday. The company had one of the biggest gains on the NYSE. The pop came after Chairman and CEO Manny Chirico said he feels the apparel maker's business at J.C. Penney is strong and running "ahead of time."

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) - For an in-depth report on OncoGenex Pharmaceuticals, Inc. follow: www.BullTrends.com/stockquote/OGXI

Shares of OncoGenex Pharmaceuticals closed down 60.31% on Monday with about 3.7 million shares traded. The stock was one of the biggest decliners on the NASDAQ and hit a new 52-week low of $3.82 during intra-day trading. The company announced along with Teva Pharmaceuticals that their experimental prostate cancer treatment failed to show any statistically significant improvements when compared to standard chemotherapy in a late-stage trial.

Union Equity Inc. (OTC: UNQT) – For an in-depth report on Union Equity Inc. follow: www.BullTrends.com/stockquote/UNQT

Shares of Union Equity closed up 166% on Monday with about 1.4 million shares traded. The stock was one of the biggest gainers in the OTC market as well as one of the most actively traded despite no significant news released by the company.

AvWorks Aviation Corp. (OTC: SPLI) - For an in-depth report on AvWorks Aviation Corp. follow: www.BullTrends.com/stockquote/SPLI

Shares of SPLI closed up nearly 50% on Monday with nearly 50 million shares traded. The stock was one of the biggest gainers in the OTC market. The company has received approval from FINRA for a change of its name and symbol effective with the OTC market open on Tuesday, April 29, 2014. The Company will be listed as "Vapor Group, Inc." with a new trading symbol of "VPOR." 


Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures. 


Leave a comment...

Your Name